Thrombotic Thrombocytopenic Purpura
📧 Sign up to get email alerts when something new happens for Thrombotic Thrombocytopenic Purpura.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-09EMA Authorised: Cablivi (Caplacizumab) — Ablynx NV
The EMA authorised Cablivi (caplacizumab) for thrombotic thrombocytopenic purpura and designated it as an orphan medicine.
-
EMA approval · 2026-02-19EMA Authorised: Adzynma (rADAMTS13) — Takeda Manufacturing Austria AG
The European Medicines Agency authorized Adzynma (rADAMTS13) for the treatment of thrombotic thrombocytopenic purpura and granted orphan med…
-
CLINICAL_TRIALS approval · 2025-02-24Clinical Trial Update: Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda's TAK-755 expanded access program for congenital thrombotic thrombocytopenic purpura has been approved for marketing, enabling broade…
-
FDA approval · 2022-02-23FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CABLIVI (caplacizumab) from Genzyme, authorizing changes to the product labeling.